Find a Clinical Trial anywhere…
Participating in a clinical trial is a great way to contribute to curing, preventing and treating liver disease and its complications. Start your search here to find clinical trials that need people like you.
This trial is designed to be the initial prospective pilot investigation of the effectiveness of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplantation. No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant population have been performed. We propose the trial be conducted as a pilot clinical trial with the goal of enrolling 40 patients into each arm.
To obtain more information, please contact Beth Chiapetta: 708-216-2568 or BCHIAPPETTA@lumc.edu
University of Chicago
The purpose of this study of INC280 and PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of PDR001 administered i.v. as a single agent or in combination with INC280 administered orally in adult patients with advanced hepatocellular carcinoma (HCC).
To obtain more information, please contact Manish Sharma: 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
University of Chicago
Assessment of safety and tolerability of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) in advanced GI malignancies.
To obtain more information, please contact Ari Baron, MD: 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics of an investigational drug to treat patients with hepatitis B. Two different doses of the drug will be investigated compared to a placebo. The treatment will be assigned randomly. A total of approximately 140 subjects with hepatitis B will be enrolled. At Rush University Medical Center, we expect to recruit 2 patients.
To obtain more information, please contact Diana Goldman: (312) 563-3919 or (312) 942-1372
Cirrhosis and HCC Prevention
This study seeks to discover how well simvastatin works in preventing liver cancer in patients with liver cirrhosis. Simvastatin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
To obtain more information, please contact Kim Sipich: 312-694-1293
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion. Participants must have a history of hospitalization with OHE.
To obtain more information, please contact Kim Sipich: phone 312-694-1293, 312-694-0326
The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
To obtain more information, please contact Jeanne Gottstein: phone 312-694-0264
Simvastatin in Preventing Liver Cancer in Patients with Liver Cirrhosis
This study will test the effects of simvastatin in people with liver cirrhosis. Participants in this study will get either simvastatin or placebo, a pill that looks like the study drug but contains no medication. This will allow researchers to see if participants taking simvastatin show changes in their liver, which may indicate a lower risk of developing cancer. This study is looking for volunteers who are 18 years of age or older and have liver cirrhosis. We will enroll 80 participants.
Contact Kim Sipich at 312-694-1293 to obtain more information.